다이하이드로 벤조퓨란구조를 골격으로 하는 카이네이즈저해 화합물
    32.
    发明公开
    다이하이드로 벤조퓨란구조를 골격으로 하는 카이네이즈저해 화합물 失效
    用DIHYDROBENZOFURAN SCAFFOLD进行激酶抑制化合物

    公开(公告)号:KR1020030067161A

    公开(公告)日:2003-08-14

    申请号:KR1020020007039

    申请日:2002-02-07

    Abstract: PURPOSE: Provided are kinase inhibitory compounds with dihydrobenzofuran scaffold, which has therapeutic effect on hepatocirrhosis, rheumatism, cancer, sclerosis of the arteries, and the like. CONSTITUTION: Kinase inhibitory compound is characterized by comprising dihydrobenzofuran scaffold, and a functional group attached to the dihydrobenzofuran scaffold and providing hydrogen bond. The kinase inhibitory compound is characteristically represented by the formula(1).

    Abstract translation: 目的:提供具有二氢苯并呋喃支架的激酶抑制化合物,其具有对肝硬化,风湿病,癌症,动脉硬化等的治疗作用。 构成:激酶抑制化合物的特征在于包含二氢苯并呋喃支架和连接于二氢苯并呋喃支架并提供氢键的官能团。 激酶抑制化合物由式(1)表征。

    신규 퀴놀린 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
    33.
    发明授权
    신규 퀴놀린 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 有权
    用于预防或治疗新型喹啉化合物和含有它们的癌症的药物组合物

    公开(公告)号:KR101778938B1

    公开(公告)日:2017-09-18

    申请号:KR1020160075019

    申请日:2016-06-16

    Abstract: 본발명은암세포에대한우수한항 증식효능을나타내는퀴놀린화합물, 이의약학적으로허용가능한염, 또는수화물과, 이의제조방법및 이를유효성분으로함유하는암 질환의예방또는치료용의약조성물에관한것으로서, 상기본 발명에따른화합물, 이의약학적으로허용가능한염, 또는수화물은우수한암세포억제활성과단백질키나아제및 돌연변이키나아제의억제활성을나타내고있으므로, 부작용이적은새로운항암제로유용하게사용될수 있다.

    Abstract translation: 本发明涉及一种优良的抗 - 喹啉化合物为代表增殖作用,其药学上可接受的盐,或它们的水合物及它们的制备方法和预防或治疗的药物组合物含有与用于癌细胞的活性成分的癌症疾病, 因为这些化合物根据基本发明,其药学上可接受的盐,或水合物显示出优异的肿瘤抑制活性,并且所述蛋白激酶和所述突变体的激酶抑制活性,这种副作用可有利地具有小的新的抗癌药物使用。

    칼슘 채널에 활성을 지닌 신규 피라조일 피페라진 화합물
    38.
    发明公开
    칼슘 채널에 활성을 지닌 신규 피라조일 피페라진 화합물 有权
    吡唑基哌嗪化合物作为钙通道拮抗剂

    公开(公告)号:KR1020120125098A

    公开(公告)日:2012-11-14

    申请号:KR1020110043180

    申请日:2011-05-06

    Abstract: PURPOSE: A pyrazolyl piperazine compound with a pharmaceutical activity to a calcium channel and a pharmaceutical composition containing the same are provided to be used as a pharmaceutical composition for preventing or treating diseases of brain diseases, heart diseases, cancer, and pain. CONSTITUTION: A pyrazolyl piperazine compound is denoted by chemical formula 1. The compound of chemical formula 1 is prepared by binding piperazine compounds of chemical formula 2 and chloride compounds of chemical formula 3 under the presence of a base at 20-30 Deg. C. The base includes an organic base such as an amine-based base and an inorganic base. The reaction solvent is dichloromethane, tetrahydrofurane(THF), dimethyl formamide(DMF), dimethyl aceteamide(DMAC), and dioxane. A pharmaceutical composition for preventing brain diseases, cancer, heart diseases, or pain contains the compound of chemical formula 1.

    Abstract translation: 目的:提供对钙通道具有药学活性的吡唑基哌嗪化合物和含有该通道的药物组合物作为预防或治疗脑疾病,心脏病,癌症和疼痛疾病的药物组合物。 构成:化学式1表示吡唑基哌嗪化合物。化学式1的化合物是通过在20-30度的碱存在下将化学式2的哌嗪化合物和化学式3的氯化合物结合而制备的。 C.碱包括有机碱如胺基和无机碱。 反应溶剂为二氯甲烷,四氢呋喃(THF),二甲基甲酰胺(DMF),二甲基乙酰胺(DMAC)和二恶烷。 用于预防脑疾病,癌症,心脏病或疼痛的药物组合物含有化学式1的化合物。

Patent Agency Ranking